We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Icon (ICLR) Sustain its Surprise Streak in Q3 Earnings?
Read MoreHide Full Article
Icon Plc (ICLR - Free Report) is set to report third-quarter 2016 earnings results on Oct 20. Last quarter, the company posted earnings of $1.14 per share, a penny above the Zacks Consensus Estimate.
We note that Icon surpassed the Zacks Consensus Estimate in the last four quarters, by an average of 0.92%. Let’s see how things are shaping up for this quarter.
Factors at Play
We believe Icon’s performance will benefit from its continued investments in ICONIK, ADDPLAN and Firecrest platforms. For the global contract research organization, further upside can be expected from its rising market share. Its plus points are a growing backlog and a strong funds’ flow from mid-sized companies that are expected to drive results.
However, downside may come from pricing pressure, austerity measures and health care reforms. Also, foreign exchange movements are not favoring Icon’s results. The strong U.S. dollar against the Japanese yen and euro may impede performance in the third quarter.
Overall, the company’s activities during the July–September period were inadequate to win analysts’ confidence. As a result, the Zacks Consensus Estimate for the third quarter declined to 18 cents from 19 cents per share over the last 30 days.
Our proven model does not conclusively show that Icon is likely to beat on earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank of #1, 2 or at least 3 for this to happen. That is not the case here as you will see below.
Zacks ESP: Icon currently has an Earnings ESP of 0.00%. This is because both the Most Accurate estimate and the Zacks Consensus Estimate currently stand at $1.18.
Zacks Rank: Icon has a Zacks Rank #2 (Buy) which increases the possibility of an earnings beat. Though a favorable Zacks Rank makes the case stronger for an earnings beat, a 0.00% ESP leaves our surprise prediction inconclusive.
Note that we caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are a few stocks worth considering that, as per our model, have the right combination of elements to post an earnings beat this quarter:
Achillion Pharmaceuticals, Inc. with an Earnings ESP of +6.25% and a Zacks Rank #2.
Ascendis Pharma (ASND - Free Report) with an Earnings ESP of +15.49% and a Zacks Rank #2.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Can Icon (ICLR) Sustain its Surprise Streak in Q3 Earnings?
Icon Plc (ICLR - Free Report) is set to report third-quarter 2016 earnings results on Oct 20. Last quarter, the company posted earnings of $1.14 per share, a penny above the Zacks Consensus Estimate.
We note that Icon surpassed the Zacks Consensus Estimate in the last four quarters, by an average of 0.92%. Let’s see how things are shaping up for this quarter.
Factors at Play
We believe Icon’s performance will benefit from its continued investments in ICONIK, ADDPLAN and Firecrest platforms. For the global contract research organization, further upside can be expected from its rising market share. Its plus points are a growing backlog and a strong funds’ flow from mid-sized companies that are expected to drive results.
However, downside may come from pricing pressure, austerity measures and health care reforms. Also, foreign exchange movements are not favoring Icon’s results. The strong U.S. dollar against the Japanese yen and euro may impede performance in the third quarter.
Overall, the company’s activities during the July–September period were inadequate to win analysts’ confidence. As a result, the Zacks Consensus Estimate for the third quarter declined to 18 cents from 19 cents per share over the last 30 days.
ICON PLC Price and EPS Surprise
ICON PLC Price and EPS Surprise | ICON PLC Quote
Earnings Whispers
Our proven model does not conclusively show that Icon is likely to beat on earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank of #1, 2 or at least 3 for this to happen. That is not the case here as you will see below.
Zacks ESP: Icon currently has an Earnings ESP of 0.00%. This is because both the Most Accurate estimate and the Zacks Consensus Estimate currently stand at $1.18.
Zacks Rank: Icon has a Zacks Rank #2 (Buy) which increases the possibility of an earnings beat. Though a favorable Zacks Rank makes the case stronger for an earnings beat, a 0.00% ESP leaves our surprise prediction inconclusive.
Note that we caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are a few stocks worth considering that, as per our model, have the right combination of elements to post an earnings beat this quarter:
WellCare Health Plans with an Earnings ESP of +5.41% and a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Achillion Pharmaceuticals, Inc. with an Earnings ESP of +6.25% and a Zacks Rank #2.
Ascendis Pharma (ASND - Free Report) with an Earnings ESP of +15.49% and a Zacks Rank #2.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>